The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...
Highlights,Sumitomo Mitsui Trust Group Inc. increased its holdings in Nurix Therapeutics by 42.7% in Q4.,Various firms have ...
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th.
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been assigned a consensus recommendation of “Moderate ...
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Nurix Therapeutics (NRIX) to $17 from $16 and keeps an Equal Weight ...
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been making waves in the biotechnology sector with its innovative approach to ...
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been making waves in the biotechnology sector with its innovative approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback